Alexander Uihlein
Endocrinology, Diabetes & Metabolism · Greenbrae, CANPI 1801043880
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,511 of the $3,764 with a category attached, or 66.7%. 14 manufacturers reported payments, led by Radius Health, Inc. at 40.8% of the total. Reporting peaked in 2019 at $1,991 and has fallen 98.7% since, to $27 in 2025.
Across 121 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Radius Health, Inc.$2K
- Amgen$1K
- Tandem Diabetes Care, Inc.$300
- Lilly USA, LLC$270
- Novo Nordisk$208
- Companion Medical, Inc.$70
- plus $196 from 8 others
Across 63 payments — averaging $1503.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$72K
- Gilead$23K
What the payments were for
- Speaking & faculty fees$3008%
- Travel & lodging$79821%
- Food & beverage$2,51167%
- Education$1554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Radius Health, Inc. | 32 | $1,537 |
| Amgen | 53 | $1,183 |
| Tandem Diabetes Care, Inc. | 1 | $300 |
| Lilly USA, LLC | 14 | $270 |
| Novo Nordisk | 8 | $208 |
| Companion Medical, Inc. | 4 | $70 |
| AstraZeneca | 2 | $35 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Abbott | 1 | $26 |
| Boehringer Ingelheim | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$300
- Tymlos$100
How this compares
$3,764 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 190 | $261,561 |
| OzempicSemaglutide | 81 | $61,370 |
| TymlosAbaloparatide | 13 | $58,032 |
| MounjaroTirzepatide | 22 | $24,913 |
| JardianceEmpagliflozin | 45 | $24,817 |
| Victoza 2-PakLiraglutide | 19 | $12,228 |
| Levothyroxine Sodium | 460 | $9,235 |
| OmnitropeSomatropin | 14 | $8,995 |
| Testosterone | 112 | $8,712 |
| Liothyronine Sodium | 58 | $3,457 |
| Methimazole | 184 | $3,272 |
| Hydrocortisone | 45 | $2,924 |
| Insulin Glargine-Yfgn | 38 | $2,729 |
| Eplerenone | 18 | $2,658 |
| SynthroidLevothyroxine Sodium | 13 | $2,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro | $270 | $286,474212 claims |
| Novo NordiskOzempic | $208 | $61,37081 claims |
| Radius Health, Inc.Tymlos | $1,537 | $58,03213 claims |
| Boehringer IngelheimJardiance | $23 | $24,81745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Greenbrae
- Steven HarrisGreenbrae$564K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.